Prostate-Specific Membrane Antigen-Targeted Site-Directed
Antibody-Conjugated Apoferritin Nanovehicle Favorably
Influences In Vivo Side Effects of Doxorubicin

J 2018

Prostate-Specific Membrane Antigen-Targeted Site-Directed Antibody-Conjugated Apoferritin Nanovehicle Favorably Influences In Vivo Side Effects of Doxorubicin

DOSTALOVA, Simona, Hana POLANSKÁ, Markéta SVOBODOVÁ, Jan BALVAN, Olga KRYSTOFOVA et. al.

Základní údaje

Originální název

Prostate-Specific Membrane Antigen-Targeted Site-Directed Antibody-Conjugated Apoferritin Nanovehicle Favorably Influences In Vivo Side Effects of Doxorubicin

Autoři

DOSTALOVA, Simona (203 Česká republika), Hana POLANSKÁ (203 Česká republika, domácí), Markéta SVOBODOVÁ (203 Česká republika, domácí), Jan BALVAN (203 Česká republika, domácí), Olga KRYSTOFOVA (203 Česká republika), Yazan HADDAD (203 Česká republika), Sona KRIZKOVA (203 Česká republika), Michal MASAŘÍK (203 Česká republika, domácí), Tomas ECKSCHLAGER (203 Česká republika), Marie STIBOROVA (203 Česká republika), Zbynek HEGER (203 Česká republika) a Vojtech ADAM (203 Česká republika, garant)

Vydání

Scientific reports, LONDON, NATURE PUBLISHING GROUP, 2018, 2045-2322

Další údaje

Jazyk

angličtina

Typ výsledku

Článek v odborném periodiku

Obor

30105 Physiology

Stát vydavatele

Velká Británie a Severní Irsko

Utajení

není předmětem státního či obchodního tajemství

Impakt faktor

Impact factor: 4.011

Kód RIV

RIV/00216224:14110/18:00104162

Organizační jednotka

Lékařská fakulta

DOI

http://dx.doi.org/10.1038/s41598-018-26772-z

UT WoS

000434777700013

Klíčová slova anglicky

doxorubicin ; apoferritin

Štítky

14110515, 14110518, rivok

Příznaky

Mezinárodní význam, Recenzováno

Změněno: 10. 2. 2019 18:16, Soňa Böhmová

Anotace

V originále

Herein, we describe the in vivo effects of doxorubicin (DOX) encapsulated in ubiquitous protein apoferritin (APO) and its efficiency and safety in anti-tumor treatment. APODOX is both passively (through Enhanced Permeability and Retention effect) and actively targeted to tumors through prostate-specific membrane antigen (PSMA) via mouse antibodies conjugated to the surface of horse spleen APO. To achieve site-directed conjugation of the antibodies, a HWRGWVC heptapeptide linker was used. The prostate cancer-targeted and non-targeted nanocarriers were tested using subcutaneously implanted LNCaP cells in athymic mice models, and compared to free DOX. Prostate cancer-targeted APODOX retained the high potency of DOX in attenuation of tumors (with 55% decrease in tumor volume after 3 weeks of treatment). DOX and non-targeted APODOX treatment caused damage to liver, kidney and heart tissues. In contrast, no elevation in liver or kidney enzymes and negligible changes were revealed by histological assessment in prostate cancer-targeted APODOX-treated mice. Overall, we show that the APO nanocarrier provides an easy encapsulation protocol, reliable targeting, high therapeutic efficiency and very low off-target toxicity, and is thus a promising delivery system for translation into clinical use.

Citovat

DOSTALOVA, Simona, Hana POLANSKÁ, Markéta SVOBODOVÁ, Jan BALVAN, Olga KRYSTOFOVA, Yazan HADDAD, Sona KRIZKOVA, Michal MASAŘÍK, Tomas ECKSCHLAGER, Marie STIBOROVA, Zbynek HEGER a Vojtech ADAM. Prostate-Specific Membrane Antigen-Targeted Site-Directed Antibody-Conjugated Apoferritin Nanovehicle Favorably Influences In Vivo Side Effects of Doxorubicin. Scientific reports. LONDON: NATURE PUBLISHING GROUP, 2018, roč. 8, č. 8867, s. 1-13. ISSN 2045-2322. Dostupné z: https://dx.doi.org/10.1038/s41598-018-26772-z.

@article{1454356,
   author = {Dostalova, Simona and Polanská, Hana and Svobodová, Markéta and Balvan, Jan and Krystofova, Olga and Haddad, Yazan and Krizkova, Sona and Masařík, Michal and Eckschlager, Tomas and Stiborova, Marie and Heger, Zbynek and Adam, Vojtech},
   article_location = {LONDON},
   article_number = {8867},
   doi = {http://dx.doi.org/10.1038/s41598-018-26772-z},
   keywords = {doxorubicin ; apoferritin},
   language = {eng},
   issn = {2045-2322},
   journal = {Scientific reports},
   title = {Prostate-Specific Membrane Antigen-Targeted Site-Directed Antibody-Conjugated Apoferritin Nanovehicle Favorably Influences In Vivo Side Effects of Doxorubicin},
   volume = {8},
   year = {2018}
}

TY  - JOUR
ID  - 1454356
AU  - Dostalova, Simona - Polanská, Hana - Svobodová, Markéta - Balvan, Jan - Krystofova, Olga - Haddad, Yazan - Krizkova, Sona - Masařík, Michal - Eckschlager, Tomas - Stiborova, Marie - Heger, Zbynek - Adam, Vojtech
PY  - 2018
TI  - Prostate-Specific Membrane Antigen-Targeted Site-Directed Antibody-Conjugated Apoferritin Nanovehicle Favorably Influences In Vivo Side Effects of Doxorubicin
JF  - Scientific reports
VL  - 8
IS  - 8867
SP  - 1-13
EP  - 1-13
PB  - NATURE PUBLISHING GROUP
SN  - 20452322
KW  - doxorubicin
KW  - apoferritin
N2  - Herein, we describe the in vivo effects of doxorubicin (DOX) encapsulated in ubiquitous protein apoferritin (APO) and its efficiency and safety in anti-tumor treatment. APODOX is both passively (through Enhanced Permeability and Retention effect) and actively targeted to tumors through prostate-specific membrane antigen (PSMA) via mouse antibodies conjugated to the surface of horse spleen APO. To achieve site-directed conjugation of the antibodies, a HWRGWVC heptapeptide linker was used. The prostate cancer-targeted and non-targeted nanocarriers were tested using subcutaneously implanted LNCaP cells in athymic mice models, and compared to free DOX. Prostate cancer-targeted APODOX retained the high potency of DOX in attenuation of tumors (with 55% decrease in tumor volume after 3 weeks of treatment). DOX and non-targeted APODOX treatment caused damage to liver, kidney and heart tissues. In contrast, no elevation in liver or kidney enzymes and negligible changes were revealed by histological assessment in prostate cancer-targeted APODOX-treated mice. Overall, we show that the APO nanocarrier provides an easy encapsulation protocol, reliable targeting, high therapeutic efficiency and very low off-target toxicity, and is thus a promising delivery system for translation into clinical use.
ER  -

DOSTALOVA, Simona, Hana POLANSKÁ, Markéta SVOBODOVÁ, Jan BALVAN, Olga KRYSTOFOVA, Yazan HADDAD, Sona KRIZKOVA, Michal MASAŘÍK, Tomas ECKSCHLAGER, Marie STIBOROVA, Zbynek HEGER a Vojtech ADAM. Prostate-Specific Membrane Antigen-Targeted Site-Directed Antibody-Conjugated Apoferritin Nanovehicle Favorably Influences In Vivo Side Effects of Doxorubicin. \textit{Scientific reports}. LONDON: NATURE PUBLISHING GROUP, 2018, roč.~8, č.~8867, s.~1-13. ISSN~2045-2322. Dostupné z: https://dx.doi.org/10.1038/s41598-018-26772-z.

Podrobný výpis o publikaci